12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fusilev levoleucovorin regulatory update

Spectrum submitted an sNDA to FDA for a Ready-to-Use formulation of Fusilev levoleucovorin. Spectrum said the Ready-to-Use formulation does not require reconstitution and is a higher strength product compared to the...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >